Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 185 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Postmenopausal Osteoporosis Clear all

Conditions: Post-Menopausal Osteoporosis
Interventions: ibandronate [Bonviva/Boniva]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Female only
Enrollment: 719 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 5
States / cities: Loma Linda, California • Lakewood, Colorado • Omaha, Nebraska + 2 more

Conditions: Post Menopausal Osteoporosis
Interventions: Ibandronate; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Female only
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 50
States / cities: Montgomery, Alabama • Chandler, Arizona • Peoria, Arizona + 46 more

Conditions: Postmenopausal Osteoporosis
Interventions: abaloparatide-sMTS; Combination Product
Lead sponsor: Radius Health, Inc.; Industry
Eligibility: 50 Years to 85 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Osteoporosis, Postmenopausal, Bone Loss, Age-related
Interventions: Blueberry Baseline, Blueberry Low, Blueberry Medium, Blueberry High; Dietary Supplement
Lead sponsor: Purdue University; Other
Eligibility: 45 Years to 70 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Osteoporosis, Fractures
Interventions: Therapeutic Touch; Procedure
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 40 Years to 85 Years · Female only
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Low Bone Density, Osteoporosis
Interventions: Exercise, DHEA; Behavioral · Dietary Supplement
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 55 Years to 85 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Osteoporosis Postmenopausal
Interventions: Risedronate (HMR4003); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 50 Years and older · Female only
Enrollment: 1,231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Breast Cancer, Osteoporosis
Interventions: biologic sample preservation procedure, dual x-ray absorptometry; Other · Procedure
Lead sponsor: NCIC Clinical Trials Group; Network
Eligibility: 35 Years and older · Female only
Enrollment: 238 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 13
States / cities: Torrance, California • Washington D.C., District of Columbia • Scarborough, Maine + 9 more

Conditions: Breast Neoplasms, Osteoporosis
Interventions: Zoledronic Acid, Letrozole; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 43
States / cities: Springdale, Arkansas • Burbank, California • Lafayette, California + 39 more

Conditions: Postmenopausal Osteoporosis
Interventions: Romozosumab, Teriparatide; Drug
Lead sponsor: Amgen; Industry
Eligibility: 55 Years to 90 Years · Female only
Enrollment: 436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 5
States / cities: Gainesville, Georgia • Bethesda, Maryland • Boston, Massachusetts + 1 more

Conditions: Osteoporosis
Interventions: denosumab, teriparatide; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 45 Years and older · Female only
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteoporosis
Interventions: ALX1-11 50 mcg, placebo, ALX1-11 75mcg, ALX1-11; Drug
Lead sponsor: Shire; Industry
Eligibility: 50 Years to 75 Years · Female only
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 1997
U.S. locations: 15
States / cities: Peoria, Arizona • Loma Linda, California • Mill Valley, California + 12 more

Conditions: Osteoporosis
Interventions: ALX1-11 (drug); Drug
Lead sponsor: Shire; Industry
Eligibility: 45 Years and older · Female only
Enrollment: 1,683 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 84
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 75 more

Conditions: Osteoporosis
Interventions: Recombinant Salmon Calcitonin (rsCT), Oral Tablet, Nasal Spray; Drug
Lead sponsor: Tarsa Therapeutics, Inc.; Industry
Eligibility: 45 Years to 70 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Postmenopausal Osteoporosis, Gut Microbiome, Menopause
Interventions: Blackcurrant (BC) extract, Placebo; Drug
Lead sponsor: University of Connecticut; Other
Eligibility: 45 Years to 70 Years · Female only
Enrollment: 159 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Osteoporosis, Bone Loss, Age Related, Postmenopausal Bone Loss, Postmenopausal Osteoporosis
Interventions: Osteoporosis Choice Decision Aid; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 50 Years to 90 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Primary Hyperparathyroidism, Bone Diseases, Metabolic, Osteoporosis, Postmenopausal, Bone Loss, Postmenopausal
Interventions: Forearm exercise program, Walking program; Other
Lead sponsor: Columbia University; Other
Eligibility: 45 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteoporosis, Osteopenia
Interventions: Alendronate, Calcium Citrate, Vitamin D; Drug · Dietary Supplement
Lead sponsor: University of Chicago; Other
Eligibility: 59 Years and older · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Osteoporosis, Postmenopausal
Interventions: Raloxifene HCL, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: Up to 80 Years · Female only
Enrollment: 7,705 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 1999
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Osteoporosis, Postmenopausal
Interventions: Experimental: 40 minute up trial, Experimental: 40 minute down trial, Experimental: Two 20 minute up trials, Experimental: Two 20 min down trials, Active Comparator: Sedentary trial; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 50 Years to 65 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Obesity, Osteoporosis
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 40 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Osteoporosis
Interventions: risedronate (including placebo); Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Osteoporosis
Interventions: SMC021 Oral calcitonin, SMC021 Placebo; Drug
Lead sponsor: Nordic Bioscience A/S; Industry
Eligibility: 55 Years to 85 Years · Female only
Enrollment: 4,665 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 3
States / cities: Gainesville, Georgia • Detroit, Michigan • Portland, Oregon

Conditions: Osteoporosis
Interventions: Romosozumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 55 Years to 85 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 9
States / cities: Tucson, Arizona • Walnut Creek, California • Gainesville, Georgia + 6 more

Search by objective public record fields.

A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva

A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis

Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Usability of Abaloparatide-solid Microstructured Transdermal System (sMTS) in Postmenopausal Women With Low Bone Mineral Density (BMD)

Effect of Blueberries on Bone Turnover

Therapeutic Touch for Wrist Fractures in Postmenopausal Women

Effects of DHEA and Exercise on Bone Marrow Fat in Postmenopausal Women

Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women

Bone Mineral Density in Postmenopausal Women at Increased Risk of Breast Cancer And Who Are Receiving Exemestane on MAP3

Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy

An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women

Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis

A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis

Open Label Extension Study of PREOS

A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women

Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis Risk in Postmenopausal Females

Osteoporosis Choice Decision Aid for Use of Bisphosphonates in Postmenopausal Women

Radius Loading in Primary Hyperparathyroidism

Texture Analysis for Postmenopausal Osteoporosis

Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis

Parameters of Exercise to Prevent Osteoporosis

Bone Metabolism After Bariatric Surgery

The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)

A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D

Transition From Alendronate to Romosozumab (AMG 785)